Last year, OncoMyx Therapeutics unveiled preclinical data showing its engineered rabbit pox virus therapy could slow tumor growth in mouse models of melanoma and bone cancer. Now, it’s unveiling more preclinical evidence, this time in non-small cell lung cancer (NSCLC).
To make its therapy, OncoMyx armed the rabbit pox virus, called myxoma virus, with genes encoding for the cytokine interleukin-12 and the sugared protein decorin. In a mouse model of NSCLC, the drug successfully slowed tumor growth, according to results unveiled at the American Association for Cancer Research (AACR) virtual annual meeting.
To read the full article on FierceBiotech, click here